2018 年饱受战争蹂躏的刚果民主共和国的埃博拉疫情：重组水疱性口炎病毒 - 扎伊尔埃博拉病毒疫苗的可接受性和患者满意度。
Ebola epidemic in war-torn Democratic Republic of Congo, 2018: Acceptability and patient satisfaction of the recombinant Vesicular Stomatitis Virus - Zaire Ebolavirus Vaccine.
机构信息
Université Catholique du Graben, Butembo, Democratic Republic of the Congo.
University of Alberta, Edmonton, Canada.
出版信息
Vaccine. 2019 Apr 10;37(16):2174-2178. doi: 10.1016/j.vaccine.2019.03.004. Epub 2019 Mar 13.
BACKGROUND
The current Ebola outbreak in Eastern Democratic Republic of the Congo (DRC) is the second largest in history and the first in which the recombinant Vesicular Stomatitis Virus - Zaire Ebolavirus (rVSV-ZEBOV) vaccine has been used at scale. We assessed side-effects, satisfaction, and attitudes toward the new vaccine.
METHODS
Cross-sectional survey questionnaire from a convenience sample of 90 vaccine recipients and 96 community controls in Eastern DRC.
RESULTS
Side-effects were reported in 75/90 (83%) vaccine recipients but only 5 (7%) and 4 (5%) reported arthralgia and rash, respectively. 76/90 (84%) vaccinees were classified as "promoters" (would recommend vaccine to others) and 6/90 (7%) as "detractors." 69/96 (72%) of unvaccinated community controls would wish to be vaccinated if supply were available. 153/186 (82%) would accept vaccination for family members.
CONCLUSIONS
The rVSV-ZEBOV vaccine was well tolerated, with high acceptability in the community during the current outbreak in the DRC.
背景
刚果民主共和国（DRC）东部目前爆发的埃博拉疫情是历史上第二大规模的疫情，也是首次大规模使用重组水疱性口炎病毒 - 扎伊尔埃博拉病毒（rVSV-ZEBOV）疫苗的疫情。我们评估了新疫苗的副作用、满意度和态度。
方法
在刚果民主共和国东部，对 90 名疫苗接种者和 96 名社区对照者的便利样本进行了横断面调查问卷调查。
结果
75/90（83%）名疫苗接种者报告了副作用，但只有 5（7%）和 4（5%）人分别报告了关节痛和皮疹。76/90（84%）名疫苗接种者被归类为“推荐者”（会向他人推荐疫苗），6/90（7%）名被归类为“贬低者”。如果供应充足，96 名未接种疫苗的社区对照者中有 69/96（72%）人希望接种疫苗。153/186（82%）人会接受为家庭成员接种疫苗。
结论
在刚果民主共和国目前的疫情中，rVSV-ZEBOV 疫苗耐受性良好，在社区中具有很高的可接受性。
Zotero 插件